At the 2026 World Economic Forum in Davos, David Sacks, the White House’s crypto czar, declared with the solemnity of a man announcing the end of winter that banks are preparing to fully adopt cryptocurrency. One imagines the bankers clutching their portfolios like children holding hands during a thunderstorm, finally assured that the lightning rods of regulation have been properly installed.
Well, slap my wallet and call me a blockchain! The crypto world in 2025 decided to get all grown up. According to the wizards at CoinGate, digital coins aren’t just for buying your latte anymore-they’re running the whole coffee shop! Asset choices, settlement shenanigans, and network hijinks all teamed up to make merchants look like crypto geniuses.
The current yield of 2.4% is, of course, a matter of present consideration, exceeding by a comfortable margin the yield offered by the broader market, as represented by the S&P 500. Indeed, the recently published financial results for the fourth quarter serve only to confirm what discerning observers have long suspected: that the company’s financial health remains remarkably robust.
Meanwhile, in a parallel universe known as the Senate Agriculture Committee, a different drama unfolds. With the flourish of a magician pulling a rabbit from a hat, they have unveiled their Digital Asset Market Clarity Act. And lo, they plan to vote on it on January 27, as if the stars themselves have aligned for this momentous occasion. Yet, in this comedy of errors, both bills must be merged before the full Senate can cast their votes. Clarity, it appears, is a dish best served cold-and very, very late.
The broader market, a surging tide, lifted many boats. Yet, to measure success solely by its rise is to mistake the surface for the depths. These three – Meta, Amazon, and PayPal – presented a more nuanced story, a whisper of resistance against the prevailing wind. Do they still hold promise as the year turns, as winter yields to a tentative spring?
The entire artificial intelligence kerfuffle, as it were, now seems to hinge on what Nvidia does with its quarterly reports. A most curious state of affairs, wouldn’t you agree? The transition, you ask how it happened? Well, it’s a story of rather clever chaps and even cleverer bits of kit.
This little dip happened whilst the price soared to a jaw-dropping all-time high of $126,080 late last year. It’s a curious case indeed, where usually a price record would send folks scrambling for their keyboards, but here we are, witnessing the opposite.
To discover a truly promising investment in this age of frenzied speculation is akin to finding a perfectly preserved rose in a dust storm. Rare, indeed. And this, I venture to suggest, is one such bloom.
By the time the bell rang, their stock was up more than fourteen percent. Which is, you know, a thing that happens.
Sarepta, peddling dreams for those afflicted by Duchenne muscular dystrophy, once held a glimmer of promise. A rare disease, yes, but a market nonetheless. Their Elevidys, a gene therapy, offered a fragile hope, a slowing of the inevitable. Then came the reports – two lives extinguished, livers failing after treatment. A ‘boxed warning’ slapped onto the product, a scarlet letter branding their ambition. They speak of restricting access to the highest-risk patients. A convenient euphemism for abandoning those who need it most.